Study guide

7.1 USP <795>/<797> Interface for Hazardous Drugs

PTCB Hazardous Drug Management Certificate Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

0.1 Exam Facts, Format & Eligibility 0.2 Content Outline, Scoring & Registration 0.3 USP <800> Big Picture & How to Use This Guide

2 USP <800> Program Administration

1.1 USP <800> Scope, Purpose & Enforcement 1.2 The NIOSH Hazardous Drug List (2024 Update) 1.3 Assessment of Risk 1.4 Designated Person, SOPs & the Hierarchy of Controls

3 Training, Compliance & Recordkeeping

2.1 Training Requirements & Medical Surveillance 2.2 Hazard Communication, SDS & OSHA Requirements 2.3 Recordkeeping & Professional Guidelines

4 Primary Engineering Controls

3.1 Containment Primary Engineering Controls (C-PEC): BSCs & CACIs 3.2 Closed System Transfer Devices (CSTDs) 3.3 Nonsterile Controls and the C-SCA Distinction

5 Secondary Engineering Controls & Facility Design

4.1 Containment Secondary Engineering Controls (C-SEC): Negative Pressure & Air Exchange 4.2 Facility Layout: Storage, Unpacking & Sink Placement 4.3 Certification, ISO Classes & Emergency Equipment

6 Facility Cleaning Procedures

5.1 The Four-Step Cleaning Process 5.2 Wipe Sampling & Action Levels 5.3 Hazardous Waste Disposal & RCRA

7 Spill Response & Cleaning PPE

6.1 Spill Kits & Spill Response Procedures 6.2 PPE During Cleaning: Glove Change Frequency & Disposal

8 Dispensing & the Compounding Interface

7.1 USP <795>/<797> Interface for Hazardous Drugs 7.2 High-Risk Oral Hazardous Drugs 7.3 Tablet Splitting & Crushing Restrictions

9 Counting, Packaging & Patient Counseling

8.1 Counting, Packaging & Dedicated Equipment 8.2 Patient Counseling & Unit-Dose Labeling

10 PPE: Gloves, Gowns & Task-Based Selection

9.1 ASTM D6978 Chemotherapy Gloves & Double Gloving 9.2 Chemo Gowns & Gown Change Frequency 9.3 Task-Based PPE Selection

11 Respiratory Protection, Eye Protection & PPE Sequencing

10.1 Respiratory & Eye/Face Protection 10.2 Donning & Doffing Sequence

12 Transport & Receiving

11.1 Receiving Hazardous Drug Shipments 11.2 Internal Transport & Storage 11.3 Damaged/Leaking Shipments & Chain of Custody

13 Exam Readiness & Final Review

12.1 Domain-by-Domain Quick Review 12.2 Common Exam Traps & Final Checklist

7.1 USP <795>/<797> Interface for Hazardous Drugs

Key Takeaways Explain This Topic AI

USP <800> is an overlay chapter — it adds hazardous-drug containment and PPE requirements on top of whichever base compounding standard already applies; it never replaces USP <795> (nonsterile) or USP <797> (sterile).

Counting, weighing, or repackaging an intact final dosage form without altering it may qualify for the Assessment of Risk pathway instead of full <795>/<797> compounding standards; reconstituting, diluting, splitting, crushing, or otherwise altering the dosage form is manipulation and requires full compliance.

A hazardous nonsterile preparation (e.g., a compounded oral suspension) must satisfy USP <795>'s facility, technique, and beyond-use-dating standards plus USP <800>'s containment requirements together.

A hazardous sterile preparation (e.g., a reconstituted IV admixture) must satisfy USP <797>'s environmental, ISO-classification, and beyond-use-dating standards plus USP <800>'s containment requirements (certified C-PEC, CSTD where feasible, full chemo PPE) together.

Two mirror-image exam traps: assuming an oral hazardous drug is exempt from <800>, and assuming <800> alone is sufficient without meeting the underlying <795>/<797> quality standards.

Last updated: July 2026

USP <795>/<797> Interface for Hazardous Drugs

On the PTCB Hazardous Drug Management exam, USP <800> is easy to mistake for a stand-alone rulebook — as if hazardous drugs lived in their own separate compounding universe. They don't. USP <800> is an overlay chapter: it adds hazardous-drug containment and PPE requirements on top of whichever base compounding-quality chapter already governs the dosage form being prepared. Questions in the Dispensing Final Dosage Forms domain frequently test whether you understand this interface — which standard applies, and whether it applies instead of or in addition to another.

Why the Interface Exists

USP <795> and USP <797> exist independently of hazardous-drug status. They set the baseline quality bar for any compounded preparation — nonsterile or sterile — because a patient needs a correctly formulated, correctly dated, uncontaminated product no matter what the active ingredient is. USP <800> was written afterward, specifically to address occupational exposure risk for the personnel preparing and handling those preparations. Rather than duplicating <795>'s or <797>'s facility and technique requirements, USP <800> was designed to reference and add to them. That is why exam questions about this interface work as a two-step lookup instead of a single merged chapter.

Three Chapters, Three Jobs

Chapter What It Governs Applies To

USP <795> Nonsterile compounding quality standards — facility, equipment, technique, beyond-use dating (BUD) Any nonsterile preparation (oral liquids, capsules, ointments), hazardous or not

USP <797> Sterile compounding quality standards — environmental monitoring, ISO classification, aseptic technique, BUD Any sterile preparation (IV admixtures, injectables), hazardous or not

USP <800> Hazardous drug containment and PPE requirements Layers on top of <795> or <797> whenever the drug being handled appears on the current NIOSH hazardous drug list

The critical exam point: <800> does not replace <795> or <797>. A hazardous sterile admixture must satisfy the sterile compounding standards of <797> and the containment requirements of <800> at the same time — neither chapter substitutes for the other.

Two Questions That Decide Which Standard Applies

Before answering a dispensing-interface question, work through two things in order:

Is the final product sterile or nonsterile? This determines whether <795> or <797> is the base standard.

Does the activity involve compounding or manipulation, or is it only counting, weighing, or repackaging an already-finished dosage form? This determines whether the Assessment of Risk (AoR) pathway, covered in Chapter 1, is even available for the task. An AoR is eligible only for final dosage forms that require no manipulation. Reconstituting, mixing, diluting, splitting, crushing, or otherwise altering the dosage form is compounding, and compounding always pulls the task into full <795>/<797> territory.

Worked Contrast: Same Drug Class, Three Different Answers

Counting whole tablets. A technician counts intact tamoxifen 20 mg tablets from a manufacturer's stock bottle into a dispensing vial for a 30-day prescription. Nothing about the tablet is altered, so no compounding occurs — this task is a candidate for the AoR pathway rather than full <795> facility requirements, though the technician still wears single chemotherapy-rated gloves as the <800> floor.

Compounding a nonsterile suspension. A caregiver needs a liquid form of methotrexate for a patient who cannot swallow tablets. Turning tablets into a suspension is manipulation, not counting. Full USP <795> quality standards apply — a dedicated nonsterile compounding area, a documented formulation and BUD, trained personnel — and USP <800> containment requirements (dedicated HD-only equipment, chemo PPE, a contained compounding space) apply on top.

Reconstituting a sterile admixture. A technician reconstitutes a NIOSH-listed antineoplastic injectable for infusion. This is sterile compounding, so USP <797>'s environmental monitoring, ISO classification, and BUD standards apply as the base layer. Because the drug is hazardous, USP <800> adds its own requirement that the work happen inside a certified containment primary engineering control (a Class II BSC or a CACI), using a closed system transfer device (CSTD) where the dosage form allows, with full chemotherapy-rated PPE.

Decision Matrix

  • Activity Sterile or Nonsterile? Compounding/Manipulation? Governing Standard(s)
  • Counting whole HD tablets into a dispensing vial N/A — not compounded No AoR pathway (Ch. 1) + <800> PPE floor
  • Crushing or splitting an HD tablet Nonsterile Yes <795> + <800>
  • Compounding an oral HD suspension from tablets or powder Nonsterile Yes <795> + <800>
  • Reconstituting or preparing a sterile HD admixture Sterile Yes <797> + <800>
  • Common Exam Traps

Two mirror-image mistakes show up repeatedly on this topic:

“Oral means <800> doesn't apply.” Wrong — an oral final dosage form on the NIOSH list still triggers <800>'s containment/PPE floor, and if it requires compounding, it triggers full <795> as well.

“<800> is the whole rulebook.” Also wrong — <800> never stands alone. It cannot be satisfied by PPE and engineering controls if the underlying activity is compounding; the base <795> or <797> quality standards (facility, documentation, BUD, technique) must still be met.

Keep both directions in mind on exam day: <800> is additive, and the sterile/nonsterile split under <795>/<797> never disappears just because a drug happens to be hazardous.